Seite - 60 - in Advances in Neuroimmunology

BrainSci. 2016,6, 41 5. Stefanovic, A.N.; Stöckl, M.T.; Claessens, M.M.; Subramaniam, V.α-Synuclein oligomers distinctively permeabilizecomplexmodelmembranes.FEBSJ.2014,281, 2838–2850. [CrossRef] [PubMed] 6. Danzer,K.M.;Haasen,D.;Karow,A.R.;Moussaud,S.;Habeck,M.;Giese,A.;Kretzschmar,H.;Hengerer,B.; Kostka,M.Differentspeciesofalpha-synucleinoligomers inducecalciuminfluxandseeding. J.Neurosci. 2007,27, 9220–9232. [CrossRef] [PubMed] 7. Luth,E.S.; Stavrovskaya, I.G.;Bartels,T.;Kristal,B.S.; Selkoe,D.J. Soluble,prefibrillarα-synucleinoligomers promotecomplexI-dependent,Ca2+-inducedmitochondrialdysfunction. J.Biol. Chem.2014,289, 21490–21507. [CrossRef] [PubMed] 8. Volpicelli-Daley, L.A.; Gamble, K.L.; Schultheiss, C.E.; Riddle, D.M.; West, A.B.; Lee, V.M. Formation of α-synuclein Lewy neurite-like aggregates in axons impedes the transport of distinct endosomes. Mol. Biol. Cell2014,25, 4010–4023. [CrossRef] [PubMed] 9. Lashuel, H.A.; Petre, B.M.; Wall, J.; Simon,M.; Nowak, R.J.; Walz, T.; Lansbury, P.T. Alpha-synuclein, especially theParkinson’s disease-associatedmutants, formspore-like annular and tubularprotofibrils. J.Mol. Biol.2002,322, 1089–1102. [CrossRef] 10. Hurtig,H.I.; Trojanowski, J.Q.;Galvin, J.; Ewbank,D.; Schmidt,M.L.;Lee,V.M.;Clark,C.M.;Glosser,G.; Stern, M.B.; Gollomp, S.M.; et al. Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson’sdisease.Neurology2000,54, 1916–1921. [CrossRef] [PubMed] 11. Tanaka, M.; Kim, Y.M.; Lee, G.; Junn, E.; Iwatsubo, T.; Mouradian, M.M. Aggresomes formed by alpha-synucleinandsynphilin-1arecytoprotective. J.Biol. Chem. 2004,279, 4625–4631. [CrossRef] [PubMed] 12. Reeve,A.;Simcox,E.;Turnbull,D.AgeingandParkinson’sdisease:Whyisadvancingagethebiggest risk factor?AgeingRes. Rev. 2014,14, 19–30. [CrossRef] [PubMed] 13. Hirsch,E.;Graybiel,A.M.;Agid,Y.A.Melanizeddopaminergicneuronsaredifferentially susceptible to degeneration inParkinson’sdisease.Nature1988,334, 345–348. [CrossRef] [PubMed] 14. Dias,V.; Junn,E.;Mouradian,M.M.The roleofoxidative stress inParkinson’sdisease. J. ParkinsonsDis. 2013,3, 461–491. [PubMed] 15. Bharath,S.;Hsu,M.;Kaur,D.;Rajagopalan,S.;Andersen, J.K.Glutathione, ironandParkinson’sdisease. Biochem.Pharmacol. 2002,64, 1037–1048. [CrossRef] 16. Venkateshappa, C.; Harish, G.; Mythri, R.B.; Mahadevan, A.; Bharath, M.M.; Shankar, S.K. Increased oxidativedamageanddecreasedantioxidantfunctioninaginghumansubstantianigracomparedtostriatum: Implications forParkinson’sdisease.Neurochem.Res. 2012,37, 358–369. [CrossRef] [PubMed] 17. Paolicelli, R.C.; Gross, C.T. Microglia in development: Linking brain wiring to brain environment. NeuronGliaBiol.2011,7, 77–83. [CrossRef] [PubMed] 18. Schafer,D.P.;Lehrman,E.K.;Kautzman,A.G.;Koyama,R.;Mardinly,A.R.;Yamasaki,R.;Ransohoff,R.M.; Greenberg,M.E.; Barres, B.A.; Stevens, B.Microglia sculpt postnatal neural circuits in an activity and complement-dependentmanner.Neuron2012,74, 691–705. [CrossRef] [PubMed] 19. Jurgens, H.A.; Johnson, R.W. Dysregulated neuronal-microglial cross-talk during aging, stress and inflammation.Exp.Neurol. 2012,233, 40–48. [CrossRef] [PubMed] 20. Lee,D.C.;Ruiz,C.R.;Lebson,L.;Selenica,M.-L.B.L.;Rizer, J.;Hunt, J.B.;Rojiani,R.;Reid,P.;Kammath,S.; Nash,K.; etal.Agingenhancesclassicalactivationbutmitigatesalternativeactivation in thecentralnervous system.Neurobiol. Aging2013,34, 1610–1620. [CrossRef] [PubMed] 21. Norden,D.M.;Muccigrosso,M.M.;Godbout, J.P.Microglialprimingandenhancedreactivity tosecondary insult inaging,andtraumaticCNSinjury,andneurodegenerativedisease.Neuropharmacology2015,96, 29–41. [CrossRef] [PubMed] 22. Hickman, S.E.; Kingery, N.D.; Ohsumi, T.K.; Borowsky, M.L.; Wang, L.C.; Means, T.K.; El Khoury, J. The microglial sensomerevealedbydirectRNAsequencing.Nat.Neurosci. 2013,16, 1896–1905. [CrossRef] [PubMed] 23. Cho,S.-H.H.;Chen,J.A.;Sayed,F.;Ward,M.E.;Gao,F.;Nguyen,T.A.;Krabbe,G.;Sohn,P.D.;Lo,I.;Minami,S.; et al. SIRT1deficiency inmicroglia contributes to cognitivedecline inagingandneurodegenerationvia epigenetic regulationof IL-1β. J.Neurosci. 2015,35, 807–818. [CrossRef] [PubMed] 24. McGeer, P.L.; Itagaki, S.; Akiyama,H.;McGeer, E.G.Rate of cell death inparkinsonism indicates active neuropathologicalprocess.Ann.Neurol. 1988,24, 574–576. [CrossRef] [PubMed] 25. Knott, C.; Stern, G.; Wilkin, G.P. Inflammatory regulators in Parkinson’s disease: iNOS, lipocortin-1, and cyclooxygenases-1and-2.Mol.Cell.Neurosci. 2000,16, 724–739. [CrossRef] [PubMed] 60